Consider PrNEXTSTELLIS®

NEXTSTELLIS is the **first** and **only** combined oral contraceptive (COC) containing **estetrol (E4)** in Canada (15 mg E4/3 mg DRSP).[1,2*]

NEXTSTELLIS (estetrol monohydrate [E4] and drospirenone [DRSP]) is indicated for the prevention of pregnancy.[1]

MECHANISM OF ACTION: E4 SELECTIVITY

In addition to DRSP, **NEXTSTELLIS contains E4, an estrogen with high selectivity for estrogen receptors**, binding to both ERα and ERβ, with a 4–5 times higher affinity for ERα vs. ERβ. **It acts as an agonist on the vagina, uterus, endometrium, bones, and brain, and an antagonist in breast tissues.**[1†]

NEXTSTELLIS offers the convenience of a **24/4 dosing regimen.**[1‡]

Please refer to the NEXTSTELLIS Product Monograph for complete dosing and administration information.

* Comparative clinical significance has not been established.
† Clinical significance is unknown.
‡ Each pack contains 24 pink active tablets and 4 white inert tablets. One hormone-containing pink tablet should be taken daily for 24 days, followed by one hormone-free white tablet for 4 days. Tablets should be taken at roughly the same time daily.

Please consult the Product Monograph at pdf.hres.ca/dpd_pm/00078097.PDF for important information about:

- Contraindications in patients with hypersensitivities to the drug, with a history of or actual thrombophlebitis or thromboembolic disorders, who have severe or multiple risk factor(s) for arterial or venous or thrombosis, who have a history of or actual cerebrovascular disorders, myocardial infarction or coronary artery disease, valvular heart disease with complications, prodromi of a thrombosis, migraine with focal aura, or pancreatitis if associated with severe hypertriglyceridaemia, who have active liver disease or history of or actual benign or malignant liver tumours or hepatic dysfunction, carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia, undiagnosed abnormal vaginal bleeding, steroid-dependent jaundice or cholestatic jaundice, or history of jaundice of pregnancy, any ocular lesion(s), a known or suspected pregnancy, and/or renal or adrenal insufficiency
- Most serious warnings and precautions regarding cigarette smoking and the risk of serious cardiovascular events, particularly in women over the age of 35 and with the number of cigarettes smoked, and regarding sexually transmitted infections
- Other relevant warnings and precautions regarding discontinuation due to thromboembolic and cardiovascular disorders, venous stasis and vascular thrombosis-related conditions, visual defects, severe headaches or worsening of migraine headaches, epileptic seizures, or papilledema or ophthalmic vascular lesions, monitoring serum potassium, contraindications in those at risk of hyperkalemia predisposing conditions, using strong CYP3A4 inhibitors, who have active liver disease, hepatic dysfunction or history of or actual benign or malignant liver tumours, known or suspected carcinoma of the breast, endometrium or other known or suspected estrogen-dependent neoplasia, and those at arterial thromboembolism or venous thromboembolism risk, observation in diabetic patients, patients with fibroids, the risk of cervical cancer, adverse lipid changes, worsening inflammatory bowel diseases, developing gallbladder disease, chloasma, thromboembolic complications after major surgery or inducing symptoms in hereditary angioedema, the need for thorough history and physical examination prior to use of NEXTSTELLIS, regular follow-up visit examinations as outlined per recommendations of the Canadian Task Force on the Periodic Health Examination, discontinuation for migraine evaluation, retinal vascular thrombosis risk, or pregnancy occurrence, caution in emotional disturbances or BMI >35 kg/m^2
- Clinical use, adverse reactions, drug interactions and dosing/administration instructions

The Product Monograph is also available by calling 1-855-331-0830.

References: 1. NEXTSTELLIS Product Monograph, Searchlight Pharma Inc. December 20, 2024.
2. Searchlight Pharma Inc. Data on File. 2024.

Searchlight Pharma Inc.
1600 Notre Dame St. West, Suite 312
Montréal, Québec H3J 1M1
www.searchlightpharma.com

Printed in Canada – March 2025

SEARCHLIGHT PHARMA

REVIEWED BY PAAB

nextstellis